Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency

Trial Profile

Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Therapeutic Use
  • Sponsors Kamada
  • Most Recent Events

    • 06 May 2015 According to Kamada media release, based on the results from this trial the company is planning to submit a Marketing Authorization Application with the European Medicines Agency for Conditional Approval of inhaled AAT therapy to treat AATD patients.
    • 06 May 2015 According to Kamada media release, results will be presented at the upcoming American Thoracic Society (ATS) 2015 International Conference.
    • 24 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top